Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in CRVS held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 7.2M | $104.8M | 0.0% | 8.521% | 2.21% |
| 2 | BlackRock, Inc. | 6.2M | $90.1M | +21.8% | 7.326% | 0.00% |
| 3 | STATE STREET CORP | 3.6M | $52.2M | +27.9% | 4.241% | 0.00% |
| 4 | ADAMS STREET PARTNERS LLC | 3.3M | $47.9M | 0.0% | 3.895% | 18.41% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 3.2M | $47.3M | β | 3.846% | 0.00% |
| 6 | Vivo Capital, LLC | 2.8M | $41.0M | +25.6% | 3.337% | 3.43% |
| 7 | MORGAN STANLEY | 2.5M | $36.6M | -30.0% | 2.972% | 0.00% |
| 8 | Deep Track Capital, LP | 2.5M | $36.5M | β | 2.963% | 0.75% |
| 9 | WELLINGTON MANAGEMENT GROUP LLP | 2.3M | $33.9M | +636.8% | 2.757% | 0.01% |
| 10 | PERCEPTIVE ADVISORS LLC | 2.3M | $33.5M | +231.1% | 2.726% | 0.66% |
| 11 | COMMODORE CAPITAL LP | 2.3M | $33.0M | β | 2.686% | 1.91% |
| 12 | Foresite Capital Management VI LLC | 1.8M | $26.8M | +32.6% | 2.178% | 5.82% |
| 13 | BRAIDWELL LP | 1.8M | $25.6M | β | 2.084% | 0.86% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 1.7M | $25.1M | +16.3% | 2.037% | 0.00% |
| 15 | MPM Oncology Impact Management LP | 1.7M | $24.5M | -39.0% | 1.992% | 1.89% |
| 16 | GOLDMAN SACHS GROUP INC | 1.5M | $22.5M | +178.5% | 1.832% | 0.00% |
| 17 | Hood River Capital Management LLC | 1.3M | $19.5M | β | 1.588% | 0.20% |
| 18 | Boxer Capital Management, LLC | 1.1M | $16.1M | β | 1.308% | 2.11% |
| 19 | Polar Capital Holdings Plc | 1.1M | $15.7M | β | 1.273% | 0.06% |
| 20 | Catalio Capital Management, LP | 892K | $13.0M | β | 1.061% | 2.73% |
| 21 | MILLENNIUM MANAGEMENT LLC | 866K | $12.7M | +25.8% | 1.030% | 0.01% |
| 22 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 768K | $11.2M | +15.4% | 0.914% | 0.00% |
| 23 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 750K | $11.0M | β | 0.892% | 0.02% |
| 24 | EMERALD ADVISERS, LLC | 686K | $10.0M | β | 0.816% | 0.32% |
| 25 | VANGUARD PORTFOLIO MANAGEMENT LLC | 670K | $9.8M | β | 0.797% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in CRVS β a direct measure of their conviction.
Filings activity in CRVS during Q1 2026, grouped by how each filer changed its position.
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 157 | +30% | 97.39% | +61.40 pp | $977M | +171% |
| Q4 2025 | 121 | +20% | 35.99% | +5.78 pp | $361M | +19% |
| Q3 2025 | 101 | +8.6% | 30.21% | +13.82 pp | $303M | +84% |
| Q2 2025 | 93 | +9.4% | 16.39% | +5.42 pp | $164M | +49% |
| Q1 2025 | 85 | +0.0% | 10.97% | 9.34 pp | $110M | 46% |
| Q4 2024 | 85 | +39% | 20.31% | +4.49 pp | $204M | +28% |
| Q3 2024 | 61 | +30% | 15.82% | +10.83 pp | $159M | +217% |
| Q2 2024 | 47 | β | 4.99% | β | $50M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying CRVS stock.
Based on Q1 2026 13F filings, institutional ownership of Corvus Pharmaceuticals, Inc. stands at 97.4%, held across 157 reporting institutions.
ORBIMED ADVISORS LLC is the largest reported institutional holder of CRVS, with approximately 7,165,006 shares worth $0.10B as of Q1 2026.
Yes β 2 widely-followed marquee investors appear among the top 25 institutional holders of CRVS, including MILLENNIUM MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP.
Our composite Smart Money Score for CRVS is 75 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
66 institutions opened new positions in CRVS during Q1 2026, while 30 fully exited. 83 added to existing positions and 8 trimmed.
CRVS institutional ownership rose by 61.40 percentage points quarter-over-quarter, with a net change of +36 holders.
The top 10 institutions account for 53.6% of all reported 13F value in CRVS, and the top 25 account for 81.9%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Corvus Pharmaceuticals, Inc. (CRVS) Institutional Ownership